PTAB challenges

Proceedings overview

One AIA trial proceeding has been filed against US Patent 11084865. The proceeding is IPR2025-01268, which has a status of Discretionary Denial. This means the patent has not been challenged on its merits through an IPR and the claims remain untested and intact.

IPR2025-01268 — Fresenius Kabi SwissBioSim GmbH et al. v. Eric FURFINE et al

• Type: Inter Partes Review
• Filed: 2025-07-14
• Status: Discretionary Denial
• Judge panel: Not publicly available yet for this stage of the proceeding.
• Petition grounds: Not publicly available yet as institution was denied.
• Institution decision: Denied (date not available, but indicated by "last modified 2026-03-09" and "status: Discretionary Denial"). The reasoning for discretionary denial is not yet publicly detailed in the provided data.
• Final Written Decision: Not applicable; institution was denied.
• Settlement / termination: Not applicable; institution was denied.
• Appeal: Not applicable; institution was denied, so there is no Final Written Decision to appeal.
• Defensive value: The discretionary denial of this IPR means that the claims of US11084865 remain unchallenged by this specific petitioner. Any future defendant facing assertion of this patent would still have the opportunity to challenge the patent through new IPRs or other validity arguments in district court, as estoppel under § 315(e)(2) does not apply when institution is denied.

Strategic summary

All claims of US Patent 11084865 are currently UNTESTED through AIA trial proceedings. The single IPR filed, IPR2025-01268, was denied institution on discretionary grounds, meaning the merits of the patentability challenge were not decided by the PTAB. Consequently, no claims have been canceled or sustained through an IPR FWD.

The estoppel landscape remains open for future challengers. Since institution of IPR2025-01268 was denied, Fresenius Kabi SwissBioSim GmbH et al. and their privies are not barred by § 315(e)(2) from raising any grounds that could have been raised in this petition in a subsequent district court litigation or a new IPR (though a new IPR would face its own institution challenges). For a defendant currently being asserted against, all prior-art grounds remain available for potential invalidity arguments, either in court or in a newly filed PTAB petition.

There are no apparent pattern signals of multiple IPR filings by the same petitioner or aggressive PTAB appeals by the patent owner based on the information provided. The discretionary denial suggests that the PTAB, for reasons not yet fully detailed in this dataset, opted not to proceed with a trial.

Recommended next steps

Since there is no active PTAB proceeding and the single filed IPR was denied institution, the claims of US11084865 are currently considered valid from a PTAB perspective. If you are a defendant facing assertion of this patent, you would need to evaluate the claims and prior art independently to determine if a new IPR challenge is warranted. The absence of instituted PTAB activity might suggest that the patent has not faced a robust validity challenge, or that previous challenges (like the denied IPR) were found to be procedurally deficient or did not meet the institution threshold for discretionary reasons. Reviewing the PTAB's detailed decision for the discretionary denial of IPR2025-01268 (when publicly available on USPTO PTAB Decisions) would be crucial for understanding the specific reasons for denial and informing any future strategy.